Marker Therapeutics Inc (MRKR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.18-4.84%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Marker Therapeutics is a clinical-stage biotech focused on cancer therapies. It aims to extend cash through Q4 2026. The company plans to improve revenue after recent declines. Recent earnings beats show some progress.
Revenue is falling sharply and losses continue. The company is not profitable. Cash may run out before new revenue grows.
The price is about 43% below our fair value near $3. Analysts expect revenue to drop about 50%. We see some chance of recovery but risks remain.
Breaks if: Cash runway falls short of Q4 2026
Breaks if: Significant management instability or turnover
Revenue growth falls below -50% next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with high risk. The company is currently loss-making and has shown weak recent financial performance, but it benefits from a favorable sector backdrop.
The market appears to have priced in a low level of fragility, indicating that expectations are somewhat justified. MRKR is seen as cheap compared to its peers, but there is a slight negative expectations gap.
Management is focused on extending the cash runway and improving revenue generation, but recent results show declining revenue. The near-term risk of missing earnings is significant due to the company's smaller size and the high miss rate in its industry.
The long-term thesis hinges on whether MRKR can improve its revenue generation and extend its cash runway. Additionally, the performance of sector bellwethers and overall economic conditions will be crucial in determining MRKR's trajectory.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1-3 years, MRKR's performance will depend on its ability to navigate financial challenges while leveraging sector momentum. Not investment advice.